THERAPY DOSSIER · th-1def6b263ac6

Actinonin (general matrix metalloproteinase inhibitor); oestrogen tested separately

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31451729 ↗2019Reported benefit

Effect of Protease Inhibitors in Healing of the Vaginal Wall.

RatWoundSprague-DawleyFemaleLocal application at the time of surgeryAt the time of surgery

Model: Surgical injury of the vaginal wall, including ovariectomised animals

Actinonin significantly abrogated injury-induced degradation of fibulin-5 and rescued the negative effects of injury on biomechanics, histomorphology and elastic fibres. Oestrogen did not alter acute fibulin-5 loss at 12 to 48 h but rescued poor recovery at 7 days in ovariectomised animals.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…